Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.
- DOI
- 10.1136/bmjopen-2026-123779
- Published
- 2026 Sep 17
- Container
- BMJ open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2026-123779,
title = {Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.},
author = {Giraldi LV and Andersen JT and Jespersen J and Baden CS and Fonvig CE and Riis T and Dalhoff KP and Holm JC and Fink-Jensen A and Pagsberg AK and Christensen MB and Gade C},
year = {2026},
journal = {BMJ open},
doi = {10.1136/bmjopen-2026-123779},
url = {https://doi.org/10.1136/bmjopen-2026-123779}
}RIS
TY - JOUR TI - Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study. AU - Giraldi LV AU - Andersen JT AU - Jespersen J AU - Baden CS AU - Fonvig CE AU - Riis T AU - Dalhoff KP AU - Holm JC AU - Fink-Jensen A AU - Pagsberg AK AU - Christensen MB AU - Gade C PY - 2026 JO - BMJ open DO - 10.1136/bmjopen-2026-123779 UR - https://doi.org/10.1136/bmjopen-2026-123779 ER -
APA
LV, G., JT, A., J, J., CS, B., CE, F., T, R., KP, D., JC, H., A, F., AK, P., MB, C., & C, G. (2026). Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.. BMJ open. https://doi.org/10.1136/bmjopen-2026-123779
Source records
- pubmed · retrieved 2026-09-25T09:23:03.533Z